Biological analyses
PreclinicalBiologic
Biological analyses is one of 53 biologic programs targeting Blood-Brain Barrier. It is currently in Preclinical.
2
Indications
6
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia1 trial
Crohn's Disease1 trial
Blood-Brain Barrier1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biological analyses. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospices Civils de Lyon